Medical - Devices
Compare Stocks
5 / 10Stock Comparison
CNMD vs MMSI vs HOLX vs ATRC vs ISRG
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
Medical - Instruments & Supplies
Medical - Instruments & Supplies
Medical - Instruments & Supplies
CNMD vs MMSI vs HOLX vs ATRC vs ISRG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Instruments & Supplies | Medical - Instruments & Supplies | Medical - Instruments & Supplies | Medical - Instruments & Supplies |
| Market Cap | $1.17B | $3.72B | $16.97B | $1.41B | $161.07B |
| Revenue (TTM) | $1.37B | $1.54B | $4.13B | $552M | $10.58B |
| Net Income (TTM) | $55M | $139M | $544M | $-5M | $2.98B |
| Gross Margin | 53.6% | 48.7% | 52.8% | 75.5% | 66.3% |
| Operating Margin | 11.3% | 12.2% | 17.5% | -0.4% | 30.5% |
| Forward P/E | 8.7x | 15.5x | 17.2x | 370.7x | 43.8x |
| Total Debt | $835M | $898M | $2.63B | $88M | $303M |
| Cash & Equiv. | $41M | $449M | $1.96B | $167M | $3.37B |
CNMD vs MMSI vs HOLX vs ATRC vs ISRG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| CONMED Corporation (CNMD) | 100 | 51.9 | -48.1% |
| Merit Medical Syste… (MMSI) | 100 | 138.5 | +38.5% |
| Hologic, Inc. (HOLX) | 100 | 142.6 | +42.6% |
| AtriCure, Inc. (ATRC) | 100 | 58.1 | -41.9% |
| Intuitive Surgical,… (ISRG) | 100 | 234.6 | +134.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CNMD vs MMSI vs HOLX vs ATRC vs ISRG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CNMD is the #2 pick in this set and the best alternative if valuation efficiency is your priority.
- PEG 0.24 vs ISRG's 2.01
- Lower P/E (8.7x vs 43.8x), PEG 0.24 vs 2.01
- 2.1% yield; 2-year raise streak; the other 4 pay no meaningful dividend
MMSI is the clearest fit if your priority is defensive.
- Beta 0.71, current ratio 4.34x
HOLX ranks third and is worth considering specifically for income & stability.
- beta 0.41
- Beta 0.41 vs CNMD's 1.34, lower leverage
- +37.1% vs MMSI's -33.8%
ATRC is the clearest fit if your priority is growth exposure.
- Rev growth 14.9%, EPS growth 74.7%, 3Y rev CAGR 17.4%
ISRG carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.
- 5.5% 10Y total return vs MMSI's 214.6%
- Lower volatility, beta 1.02, Low D/E 1.7%, current ratio 4.87x
- 20.5% revenue growth vs HOLX's 1.7%
- 28.2% margin vs ATRC's -0.8%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.5% revenue growth vs HOLX's 1.7% | |
| Value | Lower P/E (8.7x vs 43.8x), PEG 0.24 vs 2.01 | |
| Quality / Margins | 28.2% margin vs ATRC's -0.8% | |
| Stability / Safety | Beta 0.41 vs CNMD's 1.34, lower leverage | |
| Dividends | 2.1% yield; 2-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +37.1% vs MMSI's -33.8% | |
| Efficiency (ROA) | 14.8% ROA vs ATRC's -0.7%, ROIC 15.0% vs -0.6% |
CNMD vs MMSI vs HOLX vs ATRC vs ISRG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
CNMD vs MMSI vs HOLX vs ATRC vs ISRG — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ISRG leads in 3 of 6 categories
CNMD leads 1 • HOLX leads 1 • MMSI leads 0 • ATRC leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ISRG is the larger business by revenue, generating $10.6B annually — 19.2x ATRC's $552M. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to ATRC's -0.8%. On growth, ISRG holds the edge at +23.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.4B | $1.5B | $4.1B | $552M | $10.6B |
| EBITDAEarnings before interest/tax | $219M | $290M | $974M | $13M | $3.8B |
| Net IncomeAfter-tax profit | $55M | $139M | $544M | -$5M | $3.0B |
| Free Cash FlowCash after capex | $124M | $274M | $1000M | $54M | $2.8B |
| Gross MarginGross profit ÷ Revenue | +53.6% | +48.7% | +52.8% | +75.5% | +66.3% |
| Operating MarginEBIT ÷ Revenue | +11.3% | +12.2% | +17.5% | -0.4% | +30.5% |
| Net MarginNet income ÷ Revenue | +4.0% | +9.0% | +13.2% | -0.8% | +28.2% |
| FCF MarginFCF ÷ Revenue | +9.0% | +17.8% | +24.2% | +9.7% | +26.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -0.7% | +7.8% | +2.5% | +14.3% | +23.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +136.8% | +38.8% | -9.2% | +101.6% | +18.8% |
Valuation Metrics
CNMD leads this category, winning 6 of 7 comparable metrics.
Valuation Metrics
At 25.2x trailing earnings, CNMD trades at a 56% valuation discount to ISRG's 57.6x P/E. Adjusting for growth (PEG ratio), CNMD offers better value at 0.69x vs ISRG's 2.65x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.2B | $3.7B | $17.0B | $1.4B | $161.1B |
| Enterprise ValueMkt cap + debt − cash | $2.0B | $4.2B | $17.6B | $1.3B | $158.0B |
| Trailing P/EPrice ÷ TTM EPS | 25.22x | 29.26x | 30.53x | -115.83x | 57.62x |
| Forward P/EPrice ÷ next-FY EPS est. | 8.71x | 15.46x | 17.21x | 370.67x | 43.84x |
| PEG RatioP/E ÷ EPS growth rate | 0.69x | — | — | — | 2.65x |
| EV / EBITDAEnterprise value multiple | 10.17x | 13.06x | 17.39x | 77.75x | 43.62x |
| Price / SalesMarket cap ÷ Revenue | 0.85x | 2.45x | 4.14x | 2.63x | 16.00x |
| Price / BookPrice ÷ Book value/share | 1.15x | 2.38x | 3.43x | 2.70x | 9.17x |
| Price / FCFMarket cap ÷ FCF | 7.78x | 17.24x | 18.44x | 29.15x | 64.67x |
Profitability & Efficiency
ISRG leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-1 for ATRC. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to CNMD's 0.81x. On the Piotroski fundamental quality scale (0–9), HOLX scores 7/9 vs ATRC's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +5.4% | +8.9% | +11.0% | -1.0% | +16.9% |
| ROA (TTM)Return on assets | +2.4% | +5.2% | +6.1% | -0.7% | +14.8% |
| ROICReturn on invested capital | +5.8% | +7.2% | +9.4% | -0.6% | +15.0% |
| ROCEReturn on capital employed | +7.0% | +7.9% | +8.8% | -0.6% | +16.5% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 | 7 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.81x | 0.57x | 0.52x | 0.18x | 0.02x |
| Net DebtTotal debt minus cash | $794M | $450M | $667M | -$79M | -$3.1B |
| Cash & Equiv.Liquid assets | $41M | $449M | $2.0B | $167M | $3.4B |
| Total DebtShort + long-term debt | $835M | $898M | $2.6B | $88M | $303M |
| Interest CoverageEBIT ÷ Interest expense | 5.20x | 10.74x | 8.00x | 0.47x | — |
Total Returns (Dividends Reinvested)
ISRG leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ISRG five years ago would be worth $15,873 today (with dividends reinvested), compared to $2,902 for CNMD. Over the past 12 months, HOLX leads with a +37.1% total return vs MMSI's -33.8%. The 3-year compound annual growth rate (CAGR) favors ISRG at 14.4% vs CNMD's -31.1% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -6.0% | -27.9% | +1.9% | -29.2% | -19.3% |
| 1-Year ReturnPast 12 months | -31.3% | -33.8% | +37.1% | -8.3% | -15.4% |
| 3-Year ReturnCumulative with dividends | -67.3% | -26.5% | -8.5% | -41.8% | +49.6% |
| 5-Year ReturnCumulative with dividends | -71.0% | -3.6% | +15.8% | -64.2% | +58.7% |
| 10-Year ReturnCumulative with dividends | +6.6% | +214.6% | +124.3% | +95.1% | +554.2% |
| CAGR (3Y)Annualised 3-year return | -31.1% | -9.8% | -2.9% | -16.5% | +14.4% |
Risk & Volatility
HOLX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
HOLX is the less volatile stock with a 0.41 beta — it tends to amplify market swings less than CNMD's 1.34 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HOLX currently trades 100.0% from its 52-week high vs MMSI's 62.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.34x | 0.71x | 0.41x | 1.03x | 1.02x |
| 52-Week HighHighest price in past year | $61.08 | $100.19 | $76.04 | $43.18 | $603.88 |
| 52-Week LowLowest price in past year | $33.21 | $59.74 | $52.81 | $26.62 | $427.84 |
| % of 52W HighCurrent price vs 52-week peak | +62.4% | +62.2% | +100.0% | +64.4% | +75.1% |
| RSI (14)Momentum oscillator 0–100 | 49.6 | 34.9 | 69.1 | 45.0 | 42.4 |
| Avg Volume (50D)Average daily shares traded | 406K | 769K | 10.0M | 669K | 1.8M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: CNMD as "Hold", MMSI as "Buy", HOLX as "Hold", ATRC as "Buy", ISRG as "Buy". Consensus price targets imply 104.8% upside for CNMD (target: $78) vs 3.9% for HOLX (target: $79). CNMD is the only dividend payer here at 2.09% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $78.00 | $95.00 | $79.00 | $50.67 | $622.60 |
| # AnalystsCovering analysts | 21 | 13 | 42 | 19 | 55 |
| Dividend YieldAnnual dividend ÷ price | +2.1% | — | — | — | — |
| Dividend StreakConsecutive years of raises | 2 | — | — | — | — |
| Dividend / ShareAnnual DPS | $0.79 | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +4.4% | +0.8% | +1.4% |
ISRG leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CNMD leads in 1 (Valuation Metrics).
CNMD vs MMSI vs HOLX vs ATRC vs ISRG: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is CNMD or MMSI or HOLX or ATRC or ISRG a better buy right now?
For growth investors, Intuitive Surgical, Inc.
(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus 1. 7% for Hologic, Inc. (HOLX). CONMED Corporation (CNMD) offers the better valuation at 25. 2x trailing P/E (8. 7x forward), making it the more compelling value choice. Analysts rate Merit Medical Systems, Inc. (MMSI) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CNMD or MMSI or HOLX or ATRC or ISRG?
On trailing P/E, CONMED Corporation (CNMD) is the cheapest at 25.
2x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, CONMED Corporation is actually cheaper at 8. 7x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: CONMED Corporation wins at 0. 24x versus Intuitive Surgical, Inc. 's 2. 01x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — CNMD or MMSI or HOLX or ATRC or ISRG?
Over the past 5 years, Intuitive Surgical, Inc.
(ISRG) delivered a total return of +58. 7%, compared to -71. 0% for CONMED Corporation (CNMD). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus CNMD's +6. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CNMD or MMSI or HOLX or ATRC or ISRG?
By beta (market sensitivity over 5 years), Hologic, Inc.
(HOLX) is the lower-risk stock at 0. 41β versus CONMED Corporation's 1. 34β — meaning CNMD is approximately 225% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 81% for CONMED Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — CNMD or MMSI or HOLX or ATRC or ISRG?
By revenue growth (latest reported year), Intuitive Surgical, Inc.
(ISRG) is pulling ahead at 20. 5% versus 1. 7% for Hologic, Inc. (HOLX). On earnings-per-share growth, the picture is similar: AtriCure, Inc. grew EPS 74. 7% year-over-year, compared to -64. 6% for CONMED Corporation. Over a 3-year CAGR, ATRC leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CNMD or MMSI or HOLX or ATRC or ISRG?
Intuitive Surgical, Inc.
(ISRG) is the more profitable company, earning 28. 4% net margin versus -2. 1% for AtriCure, Inc. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -0. 6% for ATRC. At the gross margin level — before operating expenses — ATRC leads at 74. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CNMD or MMSI or HOLX or ATRC or ISRG more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, CONMED Corporation (CNMD) is the more undervalued stock at a PEG of 0. 24x versus Intuitive Surgical, Inc. 's 2. 01x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, CONMED Corporation (CNMD) trades at 8. 7x forward P/E versus 370. 7x for AtriCure, Inc. — 362. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CNMD: 104. 8% to $78. 00.
08Which pays a better dividend — CNMD or MMSI or HOLX or ATRC or ISRG?
In this comparison, CNMD (2.
1% yield) pays a dividend. MMSI, HOLX, ATRC, ISRG do not pay a meaningful dividend and should not be held primarily for income.
09Is CNMD or MMSI or HOLX or ATRC or ISRG better for a retirement portfolio?
For long-horizon retirement investors, Hologic, Inc.
(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41), +124. 3% 10Y return). Both have compounded well over 10 years (HOLX: +124. 3%, ATRC: +95. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CNMD and MMSI and HOLX and ATRC and ISRG?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CNMD is a small-cap quality compounder stock; MMSI is a small-cap quality compounder stock; HOLX is a mid-cap quality compounder stock; ATRC is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock. CNMD pays a dividend while MMSI, HOLX, ATRC, ISRG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.